Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04941027 · ClinicalTrials.gov registry record
Evaluating Genetic Modifiers of Cutaneous Neurofibromas in Adults With Neurofibromatosis Type 1
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 1,046
- Enrollment target
NCT04941027: Completed study, sponsored by Stanford University.
NCT04941027 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 1,046 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04941027 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 1,046 participants
- Enrollment target
Study Summary
The main goal of this protocol is to develop a well-phenotyped genetic biobank to identify genetic variants associated with the heterogeneous clinical presentations of Neurofibromatosis Type 1 (NF1). This will allow for improve understanding of NF1 pathogenesis and more personalized disease management. The investigators will conduct a GWAS analysis to identify common genetic risk variants associated with the development of cutaneous neurofibromas.
Primary Outcome
GWAS analysis will identify common genetic risk variants associated with the development of cutaneous neurofibromas in patients with NF1.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,046 participants |
| Start Date | 2021-05-07 |
| Est. Completion | 2025-11-24 |
What the finished NCT04941027 record still lists
NCT04941027 is an observational study that tracks outcomes without assigning an intervention. Its 1,046 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT04941027 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04941027 about?
NCT04941027 is a clinical study titled "Evaluating Genetic Modifiers of Cutaneous Neurofibromas in Adults With Neurofibromatosis Type 1". The main goal of this protocol is to develop a well-phenotyped genetic biobank to identify genetic variants associated with the heterogeneous clinical presentations of Neurofibromatosis Type 1 (NF1). This will allow for improve understanding of NF1 pathogenesis and more personalized disease manageme...
What is the current status of trial NCT04941027?
This trial is currently completed. The enrollment target is 1,046 participants. The study started on 2021-05-07. Estimated completion is 2025-11-24.
Who is sponsoring clinical trial NCT04941027?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06717347 · 1,046 participants · Phase 3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- NCT04505618 · 1,050 participants · NA
Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease
- NCT04511806 · 1,050 participants
Childhood Cancer Predisposition Study (CCPS)
- NCT05028972 · 1,050 participants · NA
Hearing Impairment, Strategies and Outcomes in VA Emergency Departments
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI